0000000000329315
AUTHOR
Giuliani G.
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…
Correction: ERas and COLorectal endoscopic surgery: an Italian society for endoscopic surgery and new technologies (SICE) national report (Surgical Endoscopy, (2022), 10.1007/s00464-022-09212-y)
This article was updated to correct Nicolò Fabbri's name in the listing of the ERCOLE Study Group (in Acknowledgments).
Application of myofunctional orthognathodontic biodynamic therapy (Mobt) protocol in temporomandibular disorders: Therapeutic effects in pain and anxiety management
SUMMARY Objectives. International literature on temporomandibular disorders offers show a relationship between temporomandibular disorders and psychosocial factors. This study aims to go beyond this already known relationship (fully supported by previous literature) and shows how the application of an innovative therapeutic protocol for temporomandibular disorders (called MOBT; Myofunctional Orthognathodontic Biodynamic Therapy), may generate relevant effects in respect to anxiety, pain and disorders associated to temporomandibular disorders. Method. A total of 40 patients with TMD underwent a MOBT treatment in a private clinic in Italy, and completed a self-report questionnaire for evaluat…